Avas Drug Interactions

Erythromycin: Concurrent administration with erythromycin (a known inhibitor of CYP3A4) may result in higher plasma concentrations of Avas.
Oral Contraceptives: Administration of Avas with an oral contraceptive containing norethindrone and ethinyl oestradiol produce increased plasma concentration at norethindrone and ethinyl oestradiol.
Digoxin: Administration of multiple doses of Avas with digoxin increases the steady-state plasma digoxin concentration by approximately 20%; patients taking digoxin should be monitored appropriately.
Cyclosporine, Fibric Acid Derivatives, Erythromycin, Azole Antifungals or Niacin: The risk of myopathy during treatment with drugs belonging to the class of HMG-CoA reductase inhibitors increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, azole antifungals or niacin.
Antacid: Decreased plasma concentrations of Avas may occur when administered along with an oral antacid suspension containing magnesium and aluminum hydroxides, however, LDL-C reduction is not altered.
Warfarin: Minimal decrease in prothrombin time may occur when warfarin and Avas are administered concurrently; patients receiving warfarin should be closely monitored when Avas is added to their therapy.
Cimetidine: Avas plasma concentrations and LDL-C reduction are not altered by co-administration of cimetidine.